1.20
Talphera Inc stock is traded at $1.20, with a volume of 313.29K.
It is down -4.07% in the last 24 hours and down -10.94% over the past month.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
See More
Previous Close:
$1.23
Open:
$1.24
24h Volume:
313.29K
Relative Volume:
1.03
Market Cap:
$61.76M
Revenue:
$1,000
Net Income/Loss:
$-14.25M
P/E Ratio:
-3.988
EPS:
-0.3009
Net Cash Flow:
$-11.29M
1W Performance:
-16.31%
1M Performance:
-10.94%
6M Performance:
+48.73%
1Y Performance:
+177.42%
Talphera Inc Stock (TLPH) Company Profile
Compare TLPH vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
TLPH
Talphera Inc
|
1.19 | 63.84M | 1,000 | -14.25M | -11.29M | -0.3009 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.35 | 56.30B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.52 | 42.85B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
HLN
Haleon Plc Adr
|
9.585 | 42.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
ZTS
Zoetis Inc
|
72.58 | 30.49B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
507.18 | 21.43B | 3.17B | 1.29B | 1.01B | 27.09 |
Talphera Inc Stock (TLPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-20-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| Nov-11-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-05-19 | Resumed | Credit Suisse | Outperform |
| Jul-10-19 | Resumed | Credit Suisse | Outperform |
| Apr-24-19 | Resumed | B. Riley FBR | Buy |
| Feb-15-19 | Initiated | Credit Suisse | Outperform |
| Oct-23-18 | Initiated | B. Riley FBR | Buy |
| Oct-13-17 | Downgrade | Jefferies | Buy → Hold |
| Oct-13-17 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-14-17 | Resumed | Jefferies | Buy |
| Sep-15-16 | Reiterated | ROTH Capital | Buy |
| Aug-05-16 | Downgrade | Stifel | Buy → Hold |
| Oct-30-15 | Upgrade | Jefferies | Hold → Buy |
| Oct-05-15 | Reiterated | ROTH Capital | Buy |
| Sep-02-15 | Initiated | H.C. Wainwright | Buy |
| Jul-10-15 | Resumed | ROTH Capital | Buy |
| May-06-15 | Reiterated | Mizuho | Neutral |
| May-05-15 | Reiterated | RBC Capital Mkts | Outperform |
| Mar-10-15 | Reiterated | RBC Capital Mkts | Outperform |
| Mar-09-15 | Downgrade | Mizuho | Buy → Neutral |
View All
Talphera Inc Stock (TLPH) Latest News
Talphera Inc (TLPH) Stock News Today - TradingKey
Talphera Inc. (NASDAQ: TLPH) Share Price, TLPH Stock News, TLPH Share Price & Updates - Kalkine
HC Wainwright Has Negative View of Talphera FY2029 Earnings - MarketBeat
Talphera (TLPH) Q2 2026 Earnings Call: NEPHRO CRRT-Rekrutierung erreicht 75 % - TradingKey
Talphera (TLPH) Q2 2026 Earnings Call: NEPHRO CRRT Enrollment Reaches 75% - TradingKey
Talphera, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
H.C. Wainwright reiterates Talphera stock rating on trial progress - Investing.com
H.C. Wainwright reiterates Talphera stock rating on trial progress By Investing.com - Investing.com Canada
Talphera (TLPH) Advances NEPHRO CRRT Enrollment Amid Guideline S - GuruFocus
Talphera Inc (TLPH) (Q2 2026) Earnings Call Highlights: NEPHRO S - GuruFocus
Talphera Q2 Earnings Call Highlights - marketbeat.com
Talphera: Q2 Earnings Snapshot - AOL.com
Talphera Q2 loss narrows 40%, NEPHRO study 75% enrolled - scanx.trade
Earnings call transcript: Talphera Q2 2026 meets estimates as stock slips - Investing.com
Transcript : Talphera, Inc., Q2 2026 Earnings Call, Aug 12, 2026 - marketscreener.com
Talphera (NASDAQ:TLPH) Issues Earnings Results, Meets Estimates - MarketBeat
Talphera Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Q2 2026 Talphera Inc Earnings Call Transcript - GuruFocus
TALPHERA, INC. 2026: Revenue $0 Net income ($4.31M), EPS ($0.06) — 10-Q Summary - TradingView
Talphera reports Q2 2026 net loss $4.3M, cash and investments $17.1M; NEPHRO CRRT 75% enrolled - TradingView
Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update - The Missoulian
Talphera (TLPH): Rosalind entities report 9.9% beneficial ownership cap - Stock Titan
TLPH Stock Price and Chart — NASDAQ:TLPH - TradingView
Talphera Inc expected to post a loss of 7 cents a shareEarnings Preview - TradingView
Talphera (NASDAQ:TLPH) Upgraded at Wall Street Zen - MarketBeat
Talphera Inc (TLPH) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Talphera (TLPH.US) will release its earnings report after market close on August 12. - Moomoo
Enterprise value to EBIT forward of Talphera, Inc. – DUS:R5XA - tradingview.com
Talphera Inc. (TLPH) Climbs 5.93% to $1.43, Approaches Key $1.50 Resistance ZoneScalping Stock Signals - dars.gov.et
Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026 - TradingView
Talphera schedules Q2 2026 results conference call and webcast - Bitget
TLPH|Talphera Inc|Price:1.260|Chg%:-0.090 - TradingKey
Talphera, Inc. Revenue Breakdown – NASDAQ:TLPH - TradingView
Talphera Inc (TLPH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Talphera Inc (TLPH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Talphera Inc (TLPH) Income Statement - TradingKey
Talphera Inc (TLPH) Balance Sheet - TradingKey
Talphera Inc (TLPH) Cash Flow - TradingKey
Talphera Inc. (TLPH) Slips 6.67%, Testing Support as Biotech Sentiment WeakensStock News - dars.gov.et
Talphera Inc (TLPH) Institutional Confidence - TradingKey
Talphera Inc. (TLPH) Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline Progress ContinuesDiluted EPS Report - dars.gov.et
TLPH|Talphera Inc|Price:1.350|Chg%:-0.020 - TradingKey
ALPHEA Secures $5M Strategic Funding - GlobeNewswire Inc.
Talphera Inc. (TLPH) Shows Modest Gain: Navigating Key Resistance at $1.47Monthly Profile - dars.gov.et
Talphera Inc. (TLPH) Edges Higher: Approaching Key Resistance Amid Low VolumeIPO Entry Watch - dars.gov.et
TLPH Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Surprise, Shares SlipProfit Inflection Point - po-news-eg.net
TLPH Q1 2026 Earnings: Smaller-Than-Expected Loss Drives Positive ReactionEPS Consistency Score - dars.gov.et
Talphera Inc. (TLPH) Surges 7.35% as Bulls Test Key Resistance at $1.53Retail Sentiment - dars.gov.et
Price to book forward of Talphera, Inc. – NASDAQ:TLPH - TradingView
Talphera Inc. (TLPH) Q1 2026 Earnings: EPS Beat Boosts Shares Despite No RevenueUpward Estimate Revision - dars.gov.et
Price to earnings forward of Talphera, Inc. – NASDAQ:TLPH - TradingView
Talphera Inc Stock (TLPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Talphera Inc Stock (TLPH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Angotti Vincent J. | CHIEF EXECUTIVE OFFICER |
Feb 12 '26 |
Buy |
0.81 |
105,364 |
85,587 |
586,954 |
| Aslam Shakil | Chief Medical Officer |
Feb 12 '26 |
Buy |
0.81 |
35,000 |
28,430 |
83,178 |
| Dasu Badri N | Chief Engineering Officer |
Feb 12 '26 |
Buy |
0.81 |
35,000 |
28,430 |
76,230 |
| ASADORIAN RAFFI | Chief Financial Officer |
Feb 12 '26 |
Buy |
0.81 |
45,000 |
36,554 |
91,256 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):